{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86"}]}],"title":"Overall Survival"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69"}]}],"title":"Disease-Free Survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Overall Survival - Percentage of Participants who survived Disease-Free Survival - measured from the initiation of nonsurgical treatment to either the last follow-up, disease progression, or death using intent-to-treat methodology","groups":[{"description":"Cetuximab- 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients. Hydroxyurea - 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation. Fluorouracil - continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours. Radiotherapy.","id":"OG000","title":"Advanced Head and Neck Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}